ClinicalTrials.gg
CompletedNCT02569476Updated Oct 26, 2024Results posted

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

A Phase 1 interventional study of Zanubrutinib and Obinutuzumab in B-cell Lymphoid Malignancies, sponsored by BeiGene. Completed at 14 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
119
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 120 studies in Lymphoma with a site in Australia — 24 open to participants now, 40 under way, 15 of them phase 3. Lymphoma · Australia.

Enrollment
63rd of 116
119 · median 132
Started
2016
with 1 other
Phase 1
24 of 120
6 open now
Registered
63rd of 120
by date

Among the 120 studies in Lymphoma with a site in Australia, this one is the 63rd largest by enrollment of the 116 interventional ones that give a count, is one of 2 that started in 2016, is one of 24 in phase 1, and was the 63rd registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

24 of the 120 studies in Lymphoma with a site in Australia are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Lymphoma with a site in Australia, or all of them as a file.
02

Study summary

This study evaluated the safety and preliminary efficacy of BGB-3111 (zanubrutinib) in combination with obinutuzumab in participants with B-cell lymphoid malignancies.

03

Conditions studied

  • B-cell Lymphoid Malignancies

Keywords

  • BGB-3111
  • Zanubrutinib
  • Obinutuzumab
  • Lymphoma
  • Leukemia
  • Therapeutic uses
  • B-cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years, able and willing to provide written and to comply with the study protocol.
  • Laboratory parameters as specified below:

    • Hematologic: count >40x10\^9/liter (L) (may be post-transfusion); >1.0x10\^9/L (growth factor use is allowed to bring pre-treatment neutrophils to >1.0x10\^9 cells/L if marrow infiltration is involved).
    • Hepatic: Total \<3 x upper limit normal (); and and alanine transaminase ≤3 x ULN.
    • Renal: ≥50 milliliters/minute (as estimated by the Cockcroft Gault equation or as measured by nuclear medicine scan or 24-hour urine collection); participants requiring hemodialysis will be excluded.
  • Anticipated survival of at least 6 months.
  • performance status of 0 to 2.
  • Female participants of and non-sterile males must have agreed to practice at least one of the following methods of with partner(s) throughout the study and for ≥3 months after discontinuing zanubrutinib or ≥18 months following obinutuzumab treatment, whichever was longer: total abstinence from sexual intercourse, double barrier contraception, intra uterine device or hormonal contraceptive initiated at least 3 months prior to first administration of study drug.
  • Male participants must have not donated sperm from first study drug administration, until 3 months after zanubrutinib discontinuation or 18 months following obinutuzumab treatment, whichever is longer.

Exclusion criteria

Exclusion Criteria:

  • Known central nervous system lymphoma or leukemia.
  • Known prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome.
  • Uncontrolled hemolytic anemia or idiopathic thrombocytopenia purpura.
  • History of significant cardiovascular disease.
  • Severe or debilitating pulmonary disease.
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy.
  • Prior Bruton tyrosine kinase inhibitor treatment.
  • Used medications which were strong cytochrome P450 (CYP) 3A inhibitors and strong inducers.
  • Vaccination with a within 28 days of the initiation of treatment.
  • stem cell transplantation within 6 months, or had active requiring ongoing .
  • Receipt of the following treatment prior to first administration of zanubrutinib, given with anti-neoplastic intent within 7 days, chemotherapy or radiotherapy within 3 weeks, monoclonal antibody within 4 weeks.
  • Participated in any drug study within 28 days of study entry, or not recovered from non-hematologic toxicity of any prior chemotherapy up to ≤ Grade 1 (except for alopecia).
  • History of other active within 2 years of study entry.
  • Major surgery in the past 4 weeks.
  • Active symptomatic fungal, bacterial and/or viral infection including evidence of infection with , human T cell lymphotropic virus seropositive status.
  • Inability to comply with the study procedures.
  • Pregnant or nursing women.
  • Any illness or condition that in the opinion of the investigator may have affected the safety of treatment or evaluation of any study's endpoints.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Zanubrutinib and Obinutuzumab

    In the dose-escalation part, dose levels and regimens were evaluated. In the indication-specific expansion cohorts, participants were assigned to different cohorts based on histology type.

    Drug: Zanubrutinib · Drug: Obinutuzumab

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1 : Number Of Participants Experiencing Adverse Events

    An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with obinutuzumab). An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug. A serious AE (SAE) was any untoward medical occurrence that, at any dose. * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.

    Time frame: Day 1 (first dose) through 4 years and 8 months

  2. Part 1: Number Of Participants With Clinical Laboratory Abnormalities

    Laboratory results are reported as participants with shifts towards (high directionality) or away (low directionality) from Grade 3 or Higher Toxicity.

    Time frame: Day -28 to -1 (predose) through 4 years and 8 months

  3. Part 1: Number Of Deaths

    An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with obinutuzumab). An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. An SAE was any untoward medical occurrence that, at any dose: * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.

    Time frame: Day 1 (first dose) through 4 years and 8 months

  4. Part 1: Number Of Participants Experiencing Dose-limiting Toxicity (DLT)

    Dose-limiting toxicities were defined as a toxicity or AE occurring during the DLT assessment period (first 29 days of treatment), which is not clearly attributable to a cause other than zanubrutinib and/or obinutuzumab (such as disease progression, underlying illness, concurrent illness or concomitant medication) and meets one of the following criteria: * Grade 3 or 4 drug-related non-hematologic toxicity (excluding Grade 3 nausea, vomiting, hypertension, and asymptomatic laboratory abnormalities), * Grade 4 drug-related hematologic toxicity persisting for \>14 days, * any grade toxicity, which in the judgment of the investigator or Sponsor, required removal of the participant from the study.

    Time frame: Day 1 (first dose) through 4 years and 8 months

  5. Part 1 and Part 2: Number Of Participants Achieving A Best Response Of Partial Response

    Partial response was defined as follows: * ≥ 50% reduction of serum IgM from baseline, * reduction in lymphadenopathy/splenomegaly (if present at baseline). For response assessments that occurred during cycles where a CT scan was not required, then results from prior scans (up to 12 weeks during the first 48 weeks and up to 24 weeks thereafter) could be carried forward in those participants with extramedullary disease at baseline.

    Time frame: Day 1 (first dose) through 4 years and 8 months

Secondary outcomes

  1. Part 1 and Part 2: Number Of Participants Achieving A Best Response Of Complete Response

    Complete response was defined as follows: * normal serum IgM values, * disappearance of monoclonal protein by immunofixation, * no histological evidence of bone marrow involvement, * complete resolution of lymphadenopathy/splenomegaly (if present at baseline) For response assessments that occurred during cycles where a computed tomography (CT) scan was not required, then results from prior scans (up to 12 weeks during the first 48 weeks and up to 24 weeks thereafter) could be carried forward in those participants with extramedullary disease at baseline.

    Time frame: Day 1 (first dose) through 4 years and 8 months

  2. Part 1 and Part 2: Progression-free Survival (PFS)

    Progression-free survival was defined as time (in months) from the start of treatment with zanubrutinib or obinutuzumab to the first documented disease progression or death due to any cause, whichever occurred first. Results are reported as the median months for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and non-germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL).

    Time frame: Day 1 (first dose) through 4 years and 8 months

  3. Part 1 and Part 2: Duration Of Response (DOR)

    Duration of response for responders was defined as the time (in months) from the date of the earliest qualifying response to the date of progressive disease or death due to any cause (whichever occurred earlier). Duration of response was analyzed using the same methods as the analysis for PFS. Responses after initiating new anticancer therapy, roll over to the long-term extension (LTE) study, or the first occurrence of disease progression were not considered in the analysis.

    Time frame: Day 1 (first dose) through 4 years and 8 months

  4. Part 1 and Part 2: Time To Response (TTR)

    The TTR for responders was defined as time (in months) from the start of the study treatment to the date of the earliest qualifying response. The TTR was summarized using descriptive statistics. Responses after initiating new anticancer therapy, roll over to the LTE study, or the first occurrence of disease progression were not considered in the analysis of TTR.

    Time frame: Day 1 (first dose) through 4 years and 8 months

  5. Part 1 and Part 2: Overall Survival (OS)

    Overall survival was defined as the time (in months) from the date of the start of the study treatment to death due to any cause. Participants who were alive before final database lock or discontinuation of the study (discontinued study due to reasons other than death) were censored at their last known alive date on or before database lock.

    Time frame: Day 1 (first dose) through 4 years and 8 months

  6. Part 1 and Part 2: Hematologic Improvement In Participants With CLL

    The number and percentage of participants with CLL with anemia (hemoglobin ≤110 grams/liter \[g/L\]), neutropenia (absolute neutrophil count ≤1.5 x 10\^9/L), or thrombocytopenia (platelet count ≤100 x 10\^9/L) at baseline were estimated.

    Time frame: Day 1 (first dose) through 4 years and 8 months

  7. Part 1: Area Under The Plasma Concentration-time Curve From Time 0 To The Time Of The Last Measurable Concentration (AUClast) Of Zanubrutinib

    Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7

  8. Part 1: Area Under The Plasma Concentration-time Curve From Time 0 To Infinity Time (AUC) Of Zanubrutinib

    Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7

  9. Part 1: Maximum Plasma Concentration (Cmax) Of Zanubrutinib

    Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7

  10. Part 1: Time To Maximum Plasma Concentration (Tmax) Of Zanubrutinib

    Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7

  11. Part 1: Terminal Elimination Half-life (t1/2) Of Zanubrutinib

    Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7

  12. Part 1: Apparent Clearance (CL/F) Of Zanubrutinib

    Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7

  13. Part 1: Apparent Volume Of Distribution (Vz/F) Of Zanubrutinib

    Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7

  14. Part 1 and Part 2: Steady State AUClast Of Zanubrutinib

    Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7

  15. Part 1 and Part 2: Steady State Cmax of Zanubrutinib

    Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7

  16. Part 1 and Part 2: Steady State Tmax Of Zanubrutinib

    Time frame: Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7

  17. Part 2: Number Of Participants Experiencing Adverse Events

    An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with obinutuzumab). An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. An SAE was any untoward medical occurrence that, at any dose,: * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.

    Time frame: Day 1 (first dose) through 4 years and 8 months

  18. Part 2: Number Of Participants With Clinical Laboratory Abnormalities

    Results are reported as participants with shifts towards (high directionality) or away (low directionality) from Grade 3 or Higher Toxicity.

    Time frame: Day -28 to -1 (predose) through 4 years and 8 months

  19. Part 2: Number Of Deaths

    An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with obinutuzumab). An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. An SAE was any untoward medical occurrence that, at any dose,: * resulted in death, * is life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.

    Time frame: Day 1 (first dose) through 4 years and 8 months

07

Results

Posted Nov 3, 2021

Participant flow

This study was conducted at 15 study centers in Australia, South Korea, and the United States (US). A total of 119 participants were enrolled in the study and received ≥1 dose of study treatment.

Participant flow — Overall Study
MilestoneZanubrutinib and Obinutuzumab
Started119
Completed0
Not completed119
Withdrew: Roll over to long-term extension study73
Withdrew: Death33
Withdrew: Withdrawal by subject9
Withdrew: Progressive disease at study withdrawal and death by end of study1
Withdrew: Palliative care1
Withdrew: Transitioned to long term follow up study1
Withdrew: Transitioned to long term extension study1

Outcome measures

PrimaryPart 1 : Number Of Participants Experiencing Adverse Events

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with obinutuzumab). An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug. A serious AE (SAE) was any untoward medical occurrence that, at any dose. * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.

Time frame:
Day 1 (first dose) through 4 years and 8 months
Reported as:
Count of participants · Participants
Part 1 : Number Of Participants Experiencing Adverse Events
ParticipantsPart 1: Zanubrutinib and Obinutuzumab
Any TEAE12
SAE7
PrimaryPart 1: Number Of Participants With Clinical Laboratory Abnormalities

Laboratory results are reported as participants with shifts towards (high directionality) or away (low directionality) from Grade 3 or Higher Toxicity.

Time frame:
Day -28 to -1 (predose) through 4 years and 8 months
Reported as:
Count of participants · Participants
Part 1: Number Of Participants With Clinical Laboratory Abnormalities
ParticipantsPart 1: 160 mg BIDPart 1: 320 mg QD
Leukocytes: Low Directionality10
Lymphocytes: Low Directionality13
Lymphocytes: High Directionality11
Neutrophils: Low Directionality13
Platelets: Low Directionality01
Phosphate: Low Directionality10
Urate: High Directionality01
PrimaryPart 1: Number Of Deaths

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with obinutuzumab). An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. An SAE was any untoward medical occurrence that, at any dose: * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.

Time frame:
Day 1 (first dose) through 4 years and 8 months
Reported as:
Count of participants · Participants
Part 1: Number Of Deaths
ParticipantsPart 1: Zanubrutinib and Obinutuzumab
Part 1: Number Of Deaths0
PrimaryPart 1: Number Of Participants Experiencing Dose-limiting Toxicity (DLT)

Dose-limiting toxicities were defined as a toxicity or AE occurring during the DLT assessment period (first 29 days of treatment), which is not clearly attributable to a cause other than zanubrutinib and/or obinutuzumab (such as disease progression, underlying illness, concurrent illness or concomitant medication) and meets one of the following criteria: * Grade 3 or 4 drug-related non-hematologic toxicity (excluding Grade 3 nausea, vomiting, hypertension, and asymptomatic laboratory abnormalities), * Grade 4 drug-related hematologic toxicity persisting for \>14 days, * any grade toxicity, which in the judgment of the investigator or Sponsor, required removal of the participant from the study.

Time frame:
Day 1 (first dose) through 4 years and 8 months
Reported as:
Count of participants · Participants
Part 1: Number Of Participants Experiencing Dose-limiting Toxicity (DLT)
ParticipantsPart 1: Zanubrutinib and Obinutuzumab
Part 1: Number Of Participants Experiencing Dose-limiting Toxicity (DLT)0
PrimaryPart 1 and Part 2: Number Of Participants Achieving A Best Response Of Partial Response

Partial response was defined as follows: * ≥ 50% reduction of serum IgM from baseline, * reduction in lymphadenopathy/splenomegaly (if present at baseline). For response assessments that occurred during cycles where a CT scan was not required, then results from prior scans (up to 12 weeks during the first 48 weeks and up to 24 weeks thereafter) could be carried forward in those participants with extramedullary disease at baseline.

Time frame:
Day 1 (first dose) through 4 years and 8 months
Reported as:
Count of participants · Participants
Part 1 and Part 2: Number Of Participants Achieving A Best Response Of Partial Response
ParticipantsPart 1: Zanubrutinib and Obinutuzumab
Part 1 and Part 2: Number Of Participants Achieving A Best Response Of Partial Response51
SecondaryPart 1 and Part 2: Number Of Participants Achieving A Best Response Of Complete Response

Complete response was defined as follows: * normal serum IgM values, * disappearance of monoclonal protein by immunofixation, * no histological evidence of bone marrow involvement, * complete resolution of lymphadenopathy/splenomegaly (if present at baseline) For response assessments that occurred during cycles where a computed tomography (CT) scan was not required, then results from prior scans (up to 12 weeks during the first 48 weeks and up to 24 weeks thereafter) could be carried forward in those participants with extramedullary disease at baseline.

Time frame:
Day 1 (first dose) through 4 years and 8 months
Reported as:
Count of participants · Participants
Part 1 and Part 2: Number Of Participants Achieving A Best Response Of Complete Response
ParticipantsPart 1: Zanubrutinib and Obinutuzumab
Part 1 and Part 2: Number Of Participants Achieving A Best Response Of Complete Response36
SecondaryPart 1 and Part 2: Progression-free Survival (PFS)

Progression-free survival was defined as time (in months) from the start of treatment with zanubrutinib or obinutuzumab to the first documented disease progression or death due to any cause, whichever occurred first. Results are reported as the median months for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and non-germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL).

Time frame:
Day 1 (first dose) through 4 years and 8 months
Reported as:
Median · Months
Part 1 and Part 2: Progression-free Survival (PFS)
MonthsPart 1: Zanubrutinib and Obinutuzumab
WM37.13 (6.31 to NA)
FL24.87 (11.07 to NA)
MZL40.25 (8.25 to NA)
Non-GCB DLBCL2.86 (1.71 to 7.39)
Total40.25 (27.63 to NA)
CLL/SLLNA (44.48 to NA)
SecondaryPart 1 and Part 2: Duration Of Response (DOR)

Duration of response for responders was defined as the time (in months) from the date of the earliest qualifying response to the date of progressive disease or death due to any cause (whichever occurred earlier). Duration of response was analyzed using the same methods as the analysis for PFS. Responses after initiating new anticancer therapy, roll over to the long-term extension (LTE) study, or the first occurrence of disease progression were not considered in the analysis.

Time frame:
Day 1 (first dose) through 4 years and 8 months
Reported as:
Median · Months
Part 1 and Part 2: Duration Of Response (DOR)
MonthsPart 1: Zanubrutinib and Obinutuzumab
WM35.84 (21.03 to NA)
FL39.75 (18.63 to NA)
Non-GCB DLBCL12.75 (2.89 to NA)
CLL/SLLNA (42.02 to NA)
MCLNA (2.73 to NA)
MZLNA (31.80 to NA)
SecondaryPart 1 and Part 2: Time To Response (TTR)

The TTR for responders was defined as time (in months) from the start of the study treatment to the date of the earliest qualifying response. The TTR was summarized using descriptive statistics. Responses after initiating new anticancer therapy, roll over to the LTE study, or the first occurrence of disease progression were not considered in the analysis of TTR.

Time frame:
Day 1 (first dose) through 4 years and 8 months
Reported as:
Mean · Months
Part 1 and Part 2: Time To Response (TTR)
MonthsPart 1: Zanubrutinib and Obinutuzumab
CLL/SLL3.14 ± 1.551
WM2.81 ± 0.050
FL3.32 ± 1.511
MCL2.77 ± 0.157
MZL5.62 ± 4.042
Non-GCB DLBCL2.76 ± 0.297
Total3.18 ± 1.487
SecondaryPart 1 and Part 2: Overall Survival (OS)

Overall survival was defined as the time (in months) from the date of the start of the study treatment to death due to any cause. Participants who were alive before final database lock or discontinuation of the study (discontinued study due to reasons other than death) were censored at their last known alive date on or before database lock.

Time frame:
Day 1 (first dose) through 4 years and 8 months
Reported as:
Median · Months
Part 1 and Part 2: Overall Survival (OS)
MonthsPart 1: Zanubrutinib and Obinutuzumab
Non-GCB DLBCL11.93 (3.52 to 16.53)
CLL/SLLNA (NA to NA)
WMNA (22.4 to NA)
FLNA (42.45 to NA)
MCLNA (7.92 to NA)
MZLNA (NA to NA)
SecondaryPart 1 and Part 2: Hematologic Improvement In Participants With CLL

The number and percentage of participants with CLL with anemia (hemoglobin ≤110 grams/liter \[g/L\]), neutropenia (absolute neutrophil count ≤1.5 x 10\^9/L), or thrombocytopenia (platelet count ≤100 x 10\^9/L) at baseline were estimated.

Time frame:
Day 1 (first dose) through 4 years and 8 months
Reported as:
Count of participants · Participants
Part 1 and Part 2: Hematologic Improvement In Participants With CLL
ParticipantsZanubrutinib and Obinutuzumab
Participants with anemia at baseline who had normalized hemoglobin after treatment11
Participants with neutropenia at baseline who had normalized hemoglobin after treatment3
Participants with thrombocytopenia at baseline who had normalized hemoglobin after treatment12
SecondaryPart 1: Area Under The Plasma Concentration-time Curve From Time 0 To The Time Of The Last Measurable Concentration (AUClast) Of Zanubrutinib
Time frame:
Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Reported as:
Geometric mean · nanogram/milliliter*hour
Part 1: Area Under The Plasma Concentration-time Curve From Time 0 To The Time Of The Last Measurable Concentration (AUClast) Of Zanubrutinib
nanogram/milliliter*hourZanubrutinib and Obinutuzumab
160 mg BID1123.59 ± 71.482
320 mg QD2179.54 ± 70.237
SecondaryPart 1: Area Under The Plasma Concentration-time Curve From Time 0 To Infinity Time (AUC) Of Zanubrutinib
Time frame:
Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Reported as:
Geometric mean · nanogram/milliliter*hour
Part 1: Area Under The Plasma Concentration-time Curve From Time 0 To Infinity Time (AUC) Of Zanubrutinib
nanogram/milliliter*hourZanubrutinib and Obinutuzumab
160 mg BID1324.63 ± 60.981
320 mg QD3052.47 ± 33.681
SecondaryPart 1: Maximum Plasma Concentration (Cmax) Of Zanubrutinib
Time frame:
Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Reported as:
Geometric mean · nanogram/milliliter
Part 1: Maximum Plasma Concentration (Cmax) Of Zanubrutinib
nanogram/milliliterZanubrutinib and Obinutuzumab
160 mg BID360.42 ± 90.350
320 mg QD589.37 ± 79.884
SecondaryPart 1: Time To Maximum Plasma Concentration (Tmax) Of Zanubrutinib
Time frame:
Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Reported as:
Geometric mean · hour
Part 1: Time To Maximum Plasma Concentration (Tmax) Of Zanubrutinib
hourZanubrutinib and Obinutuzumab
160 mg BID1.60 ± 38.285
320 mg QD1.73 ± 88.663
SecondaryPart 1: Terminal Elimination Half-life (t1/2) Of Zanubrutinib
Time frame:
Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Reported as:
Geometric mean · hour
Part 1: Terminal Elimination Half-life (t1/2) Of Zanubrutinib
hourZanubrutinib and Obinutuzumab
160 mg BID1.88 ± 29.532
320 mg QD1.79 ± 19.945
SecondaryPart 1: Apparent Clearance (CL/F) Of Zanubrutinib
Time frame:
Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Reported as:
Geometric mean · milliliter/hour
Part 1: Apparent Clearance (CL/F) Of Zanubrutinib
milliliter/hourPart 1: Zanubrutinib and Obinutuzumab
160 mg BID120789.1 ± 60.965
320 mg QD104832.9 ± 33.681
SecondaryPart 1: Apparent Volume Of Distribution (Vz/F) Of Zanubrutinib
Time frame:
Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Reported as:
Geometric mean · milliliter
Part 1: Apparent Volume Of Distribution (Vz/F) Of Zanubrutinib
milliliterPart 1: Zanubrutinib and Obinutuzumab
160 mg BID327343.8 ± 97.981
320 mg QD270810 ± 36.099
SecondaryPart 1 and Part 2: Steady State AUClast Of Zanubrutinib
Time frame:
Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Reported as:
Geometric mean · nanogram/milliliter*hour
Part 1 and Part 2: Steady State AUClast Of Zanubrutinib
nanogram/milliliter*hourZanubrutinib and Obinutuzumab
160 mg BID1074.1 ± 42.1
320 mg QD2003.9 ± 42.6
SecondaryPart 1 and Part 2: Steady State Cmax of Zanubrutinib
Time frame:
Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Reported as:
Geometric mean · nanogram/milliliter
Part 1 and Part 2: Steady State Cmax of Zanubrutinib
nanogram/milliliterZanubrutinib and Obinutuzumab
160 mg BID328.5 ± 52.3
320 mg QD580 ± 42.6
SecondaryPart 1 and Part 2: Steady State Tmax Of Zanubrutinib
Time frame:
Day 1 Cycle 1, Predose (within 3 hours), hours 1, 2, 4 and 7
Reported as:
Geometric mean · hour
Part 1 and Part 2: Steady State Tmax Of Zanubrutinib
hourZanubrutinib and Obinutuzumab
160 mg BID1.8 ± 67.0
320 mg QD1.9 ± 48.4
SecondaryPart 2: Number Of Participants Experiencing Adverse Events

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with obinutuzumab). An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. An SAE was any untoward medical occurrence that, at any dose,: * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.

Time frame:
Day 1 (first dose) through 4 years and 8 months
Reported as:
Count of participants · Participants
Part 2: Number Of Participants Experiencing Adverse Events
ParticipantsPart 2: Zanubrutinib and Obinutuzumab
Any AE119
SAE62
SecondaryPart 2: Number Of Participants With Clinical Laboratory Abnormalities

Results are reported as participants with shifts towards (high directionality) or away (low directionality) from Grade 3 or Higher Toxicity.

Time frame:
Day -28 to -1 (predose) through 4 years and 8 months
Reported as:
Count of participants · Participants
Part 2: Number Of Participants With Clinical Laboratory Abnormalities
ParticipantsPart 2: 160 mg BID
Hemoglobin: Low Directionality3
Leukocytes: Low Directionality7
Leukocytes: High Directionality0
Lymphocytes: Low Directionality10
Lymphocytes: High Directionality2
Neutrophils: Low Directionality11
Platelets: Low Directionality7
Alanine Aminotransferase: High Directionality1
Albumin: Low Directionality5
Alkaline Phosphatase: High Directionality1
Aspartate Aminotransferase: High Directionality1
Glucose: High Directionality3
Phosphate: Low Directionality3
Sodium: Low Directionality1
Urate: High Directionality1
SecondaryPart 2: Number Of Deaths

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product (zanubrutinib in combination with obinutuzumab). An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. An SAE was any untoward medical occurrence that, at any dose,: * resulted in death, * is life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.

Time frame:
Day 1 (first dose) through 4 years and 8 months
Reported as:
Count of participants · Participants
Part 2: Number Of Deaths
ParticipantsPart 2: Zanubrutinib and Obinutuzumab
Total deaths34
Progression of disease24
Unknown2
Acute respiratory distress syndrome1
Road traffic accident1
Bone marrow failure and metastatic skin squamous cell carcinoma1
Cardiac arrest during admission to private hospital for bowel resection for colorectal cancer1
Chest infection1
CLL/sepsis1
Metastatic breast cancer1
Undisclosed1

Adverse events

Collected over Day 1 (first dose) through 4 years and 8 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zanubrutinib and Obinutuzumab34/119 (28.6%)62/119 (52.1%)119/119 (100%)
Most frequent serious events
Showing 10 of 97
Most frequent serious events
EventZanubrutinib and Obinutuzumab
PneumoniaInfections and infestations8/119
PyrexiaGeneral disorders8/119
NeutropeniaBlood and lymphatic system disorders5/119
InfluenzaInfections and infestations4/119
Urinary tract infectionInfections and infestations4/119
CellulitisInfections and infestations3/119
GastroenteritisInfections and infestations3/119
SepsisInfections and infestations3/119
Abdominal painGastrointestinal disorders3/119
AppendicitisInfections and infestations2/119
Most frequent other events
Showing 10 of 98
Most frequent other events
EventZanubrutinib and Obinutuzumab
Upper respiratory tract infectionInfections and infestations55/119
NeutropeniaBlood and lymphatic system disorders41/119
ContusionInjury, poisoning and procedural complications39/119
FatigueGeneral disorders38/119
CoughRespiratory, thoracic and mediastinal disorders36/119
DiarrhoeaGastrointestinal disorders31/119
ThrombocytopeniaBlood and lymphatic system disorders26/119
RashSkin and subcutaneous tissue disorders23/119
NauseaGastrointestinal disorders22/119
PetechiaeSkin and subcutaneous tissue disorders18/119

Baseline characteristics

Age, Continuous
Age, Continuous(years)Zanubrutinib and Obinutuzumab
Median68 (34 to 86)
Sex: Female, Male
Sex: Female, Male(Participants)Zanubrutinib and Obinutuzumab
Female41
Male78
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zanubrutinib and Obinutuzumab
White107
Black or African American1
Asian11
Not Hispanic or Latino117
Hispanic or Latino2
Vital Signs
Vital Signs(millimeters of mercury)Zanubrutinib and Obinutuzumab
Blood Pressure (Systolic)124.5 ± 17.75
Blood Pressure (Diastolic)71.5 ± 11.46
Pulse Rate
Pulse Rate(beats/minute)Zanubrutinib and Obinutuzumab
Mean78.2 ± 13.86
Weight
Weight(kilograms)Zanubrutinib and Obinutuzumab
Mean78.95 ± 18.004
Height
Height(centimeters)Zanubrutinib and Obinutuzumab
Mean170.92 ± 9.382
Body Mass Index
Body Mass Index(kilograms/squared meter)Zanubrutinib and Obinutuzumab
Mean26.876 ± 4.9513

1 further baseline measures are reported on the registry.

08

Study locations

14 sites
  • Florida Cancer Specialists Fort Myers
    Fort Myers, Florida 33916, United States
  • Florida Cancer Specialists East
    West Palm Beach, Florida 33401, United States
  • Tennessee Oncology
    Nashville, Tennessee 37205, United States
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
  • Brisbane Clinic For Lymphoma
    Greenslopes, Queensland 4120, Australia
  • Ashford Cancer Centre Research Northeast
    Windsor Gardens, South Australia 5087, Australia
  • St Vincents Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • Barwon Health the Geelong Hospital
    Geelong, Victoria 3220, Australia
  • St Frances Xavier Cabrini Hospital
    Malvern, Victoria 3144, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • Asan Medical Center
    Seoul, Seoul Teugbyeolsi 05505, Korea, Republic of
  • Gangnam Severance Hospital, Yonsei University Health System
    Seoul, Seoul Teugbyeolsi 06273, Korea, Republic of
  • Samsung Medical Center
    Seoul, Seoul Teugbyeolsi 06351, Korea, Republic of
09

References and documents

Publications

  • Tam CS, Quach H, Nicol A, Badoux X, Rose H, Prince HM, Leahy MF, Eek R, Wickham N, Patil SS, Huang J, Prathikanti R, Cohen A, Elstrom R, Reed W, Schneider J, Flinn IW. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. Blood Adv. 2020 Oct 13;4(19):4802-4811. doi: 10.1182/bloodadvances.2020002183. PubMed 33022066 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Sep 2020, 55 months.

Results were first posted in Nov 2021, 1 year 2 months after primary completion.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 55 months is above that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2015
First posted
Oct 6, 2015
StartActual
Jan 13, 2016
Primary completionActual
Sep 2, 2020
CompletionActual
Sep 2, 2020
Results first posted
Nov 3, 2021
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02569476
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Oct 6, 2015
Start date
Jan 13, 2016
Primary completion
Sep 2, 2020
Completion
Sep 2, 2020
Results posted
Nov 3, 2021
Last update
Oct 26, 2024

Study contacts

Study Director
principal investigator · BeiGene

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion